The Impact of Circadian Misalignment on Colonic Barrier Homeostasis in Ulcerative Colitis
Part of paid clinical trials in Chicago, Illinois.
- Sponsor
- Rush University Medical Center
- Study ID
- NCT05180279
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 50 Years
- Healthy Volunteers
- Accepted
Interventions
- 7-day sleep lab — BEHAVIORALPatients will stay in 7-day sleep lab where light exposure, diet, and activity will be closely monitored. They will have two unprepped flexible sigmoidoscopies with rectal biopsy collection and stool collection. Cycles will be shifted by 12h once on Day 3 of sleep lab and be discharged after an 8 hour sleep session on Day 7.
Study Details
The purpose of this study is to investigate if circadian malalignment (unusual sleeping patterns), such as night shifts (sleeping during the day and being awake during the night time), worsens the inflammation of the gut. We hope to look at patients with Ulcerative Colitis and Healthy Controls.
Key Dates
- Start date
- Apr 1, 2021
- Status verified
- Jul 2025
- Primary completion
- Jun 5, 2024
- Completion
- Jun 5, 2024
Study Design
- Enrollment
- 19 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- BASIC_SCIENCE
Arms
- Experimental: Sleep Lab
Primary Outcome Measure
Change in Dim Light Melatonin Onset (DLMO) From Baseline (Aligned) to Circadian Misalignment Misalignment [ Time Frame: Blood is drawn every hour over 8 hours to measure plasma melatonin in dim light < 5 lux in Aligned Circadian Rhythms, and blood is drawn every hour for 12 hours under dim light in Misaligned Circadian rhythms. ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Rush University Medical Center | Chicago | Illinois | 60612 | - |
Find similar trials in Chicago, IL
By condition
By research site
Related Studies
- Improving the Quality of Care for Adults With Inflammatory Bowel DiseaseEnrolling By Invitation · Dartmouth-Hitchcock Medical Center · Los Angeles, California
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic RemissionRecruiting · University of California, San Diego · Irvine, California
- A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative ColitisPHASE2 · Recruiting · Pfizer · Little Rock, Arkansas